Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ramsay, N.
Right arrow Articles by Kersey, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ramsay, N.
Right arrow Articles by Kersey, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

Autologous bone marrow transplantation for patients with acute lymphoblastic leukemia in second or subsequent remission: results of bone marrow treated with monoclonal antibodies BA-1, BA-2, and BA-3 plus complement

N Ramsay, T LeBien, M Nesbit, P McGlave, D Weisdorf, P Kenyon, D Hurd, A Goldman, T Kim and J Kersey

Autologous bone marrow transplantation (BMT) was utilized as therapy for 23 patients with acute lymphoblastic leukemia (ALL) in second or greater remission. Bone marrow was treated in vitro with a combination of monoclonal antibodies, consisting of BA-1, BA-2, BA-3, and baby rabbit complement (BRC'). All patients were prepared for transplantation with cyclophosphamide and fractionated total body irradiation. Engraftment occurred in all 23 patients. Seven of 23 patients remain relapse-free from six to 32 months (median, 21.4 months) posttransplant. Failures were due to relapse with the exception of one patient who died of infection. This study demonstrates that autologous BMT using in vitro marrow treatment with BA-1, BA-2, BA-3, and BRC' is safe, allows engraftment, and results in prolonged survival for some patients with ALL in second or greater remission.

Volume 66, Issue 3, pp. 508-513, 09/01/1985
Copyright © 1985 by The American Society of Hematology


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 BloodHome page
D. J. Weisdorf, A. L. Billett, P. Hannan, J. Ritz, S. E. Sallan, M. Steinbuch, and N. K.C. Ramsay
Autologous Versus Unrelated Donor Allogeneic Marrow Transplantation for Acute Lymphoblastic Leukemia
Blood, October 15, 1997; 90(8): 2962 - 2968.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
J. D. Bessman
Epitopes in Medicine: The Example of the Lupus Anticoagulant
JAMA, January 22, 1988; 259(4): 573 - 573.
[Abstract] [PDF]

Home page
 ANN INTERN MEDHome page
J. L. FAHEY, G. SARNA, R. P. GALE, and R. SEEGER
Immune Interventions in Disease
Ann Intern Med, February 1, 1987; 106(2): 257 - 274.
[Abstract] [PDF]


click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 1985 by American Society of Hematology         Online ISSN: 1528-0020